Alongside a number of traditional risk factors, disturbed lung function has emerged as a key independent risk factor for cardiovascular disease in adults.[@bib1; @bib2] Recent work has identified the independent, indirect relationship between lung function and arterial stiffness, itself an independent cardiovascular predictor,[@bib3] in adults with chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD)[@bib4; @bib5] and cystic fibrosis, as well as in an unselected population of adult males.[@bib6; @bib7]

Impaired lung function has repeatedly been demonstrated in children born very preterm, independent of chronic neonatal lung disease or bronchopulmonary dysplasia (BPD).[@bib8] Both structural and functional impairments in lung function appear to persist into adulthood.[@bib9; @bib10; @bib11] The implications of preterm birth are of increasing relevance to adult physicians, given improved survival,[@bib12] tracking of lung function throughout life,[@bib13; @bib14; @bib15] and concerns that the normal age-related decline in lung function may be accelerated in such individuals.[@bib16] There is growing concern regarding the long-term effects of adverse early life events, including fetal programming, along with altered prenatal and postnatal growth patterns, which have been implicated in systolic hypertension and cardiovascular disease.[@bib17; @bib18]

The EPICure study identified significantly reduced lung function but normal brachial blood pressure (BP) in 6-year-old children born at 25 weeks completed gestation or less in the United Kingdom and Ireland compared with national standards and classmates.[@bib19; @bib20] Brachial BP traditionally has been used to assess hemodynamic status, because of its ease and ready accessibility. However, BP varies throughout the arterial tree due to variations in arterial compliance and augmentation by wave reflections; thus, peripheral BP measurements might mask altered central hemodynamics.[@bib3] Vascular properties are susceptible to change, promoting stiffness and increased wave reflection from the peripheries. Central hemodynamics were not measured in the children at 6 years of age in the EPICure study.

Several previous studies have explored the association of arterial stiffness and birth weight[@bib21; @bib22; @bib23; @bib24]; however, other studies have found inconsistent findings or have not demonstrated this association.[@bib25; @bib26] Those studies focused on intrauterine growth restriction as opposed to prematurity. Central hemodynamics were measured at 11 years of age in the EPICure study. We have reported that the augmentation index (AIx), a composite vascular parameter of arterial stiffness and global peripheral wave reflection, is increased in children born extremely preterm (EP) compared with classmates.[@bib3; @bib27] In younger individuals, AIx is more closely related to cardiovascular risk factors compared with more direct measures of large artery stiffening, such as aortic pulse wave velocity, the speed of pulsation down the aorta between the carotid and femoral pulsations, an independent predictor of cardiovascular disease in older adult subjects.[@bib3; @bib28]

Given the known impaired lung function in this population,[@bib29] we hypothesized that functional impairment would parallel altered central hemodynamics at age 11 years in children born EP. If so, then strategies to protect lung function during the neonatal period may have further important additional benefits for cardiovascular physiology and in limiting cardiovascular disease in later life.

Methods {#sec1}
=======

EPICure is a population-based study of all births between March and December 1995 in the United Kingdom and Republic of Ireland, born at 25 completed weeks of gestation or less (the data-sharing policy is available from [www.epicure.ac.uk](http://www.epicure.ac.uk)). Details of the cohort ascertainment and progress have been reported elsewhere.[@bib19; @bib20] The current investigation was part of an extensive assessment of this cohort at age 11 years comprising neurocognitive, respiratory, and other outcomes.[@bib29; @bib30; @bib31; @bib32; @bib33] Measurements were performed in school by 1 of 3 specially trained pediatricians. Schools were asked to identify up to 3 classmates as potential comparisons, matched for age, sex, and ethnic origin, 1 of whom was selected at random.[@bib29; @bib30] Classmates were excluded if born at \<37 weeks gestational age, hospitalized for respiratory complaint or had sustained tuberculosis, pneumonia, or whooping cough. Asthma and atopy were not exclusion criteria. The study protocol was approved by the Southampton and South West Hampshire Research Ethics Committee. All parents gave written consent, and the children provided verbal agreement.

Parents were contacted before the assessment to verify that their child was well and free from any respiratory tract infections to ensure that measurements were obtained during a period of clinical stability. All bronchodilators and leukotriene antagonists were withheld on the day of testing.

Standard Clinical Assessment {#sec1.1}
----------------------------

Weight was measured to the nearest 0.1 kg on a digital scale (BWB 600; Tanita, Tokyo, Japan), with the child wearing minimal clothing and barefoot. Height was recorded with the child barefoot to the nearest 0.1 cm using a Leicester stadiometer (Crawlea Medical, Birmingham, United Kingdom). Height and weight were converted to *z*-scores to adjust for sex and age.[@bib34] Questionnaires eliciting information on perinatal history, current health, therapies, and maternal smoking were completed by parents.

Hemodynamic Assessment {#sec1.2}
----------------------

The ability to include hemodynamic assessments in the protocol became available only during the latter part of the data collection period. After extensive training, a single pediatrician (J.F.) performed these measurements in children tested from September 2006 onward, at 1 hour after spirometric testing. After supine peripheral BP measurement (Omron, Kyoto, Japan) as the mean of 3 consecutive brachial artery readings, radial artery waveforms were recorded using a high-fidelity micromanometer (Millar Instruments, Houston, Texas). Pulse-wave analysis (Sphygmocor; AtCor Medical, Sydney, Australia) was used to generate a corresponding central waveform through a validated transfer function.[@bib35] The AIx is defined as the difference between the second and first systolic peaks, expressed as a percentage of pulse pressure.[@bib27] Pulse pressure amplification was calculated as the ratio of peripheral pulse pressure to central pulse pressure. Carotid-femoral (aortic) pulse wave velocity was measured as described previously,[@bib27] with results expressed as the mean of duplicate readings from traces reviewed and selected for quality by an independent experienced operator (C.M.) blinded to birth status.

Lung Function Assessment {#sec1.3}
------------------------

Baseline spirometry (Jaeger Masterscope V4.6; CareFusion, Wurzberg, Germany) was performed according to published guidelines.[@bib29] Consenting subjects were retested after administration of salbutamol 200 μg via a spacer device. A positive bronchodilator response was defined as a \>12% increase in forced expiratory volume in 1 second (FEV~1~). All data were sent to the University College London, Institute of Child Health for centralized analysis and quality control by respiratory physiologists, blinded to the children\'s birth status.[@bib29] Results were expressed as *z*-scores to adjust for sex, age, and height.[@bib36]

Statistical Analyses {#sec1.4}
--------------------

Data from lung function and hemodynamic assessments were combined with the main EPICure database for analysis. Forward stepwise regression was used to identify independent effects on AIx; predictors considered were standardized measures of lung function, sex, birth status, BPD (defined as receiving supplemental oxygen at 36 weeks postmenstrual age), maternal smoking during pregnancy, heart rate, mean arterial pressure (MAP), age, and height at time of test, in addition to their interactions with EP status. AIx values are based on unadjusted data. A *P* value \<.05 was considered to indicate statistical significance. Analyses were performed using SPSS version 11.0 (SPSS Inc, Chicago, Illinois) and Stata release 10.1 (StataCorp, College Station, Texas).

Results {#sec2}
=======

Of the 307 EPICure survivors known to be alive at age 11 years, 11 were abroad, 20 refused participation in this study, and 57 were nonresponders. Valid spirometry data were obtained from 187 of the 219 children (85%) whose parents consented to the study, 66 (35%) of whom (including 45 \[68%\] with previous BPD) also underwent hemodynamic assessment. Of 170 classmate controls contacted, 161 produced valid spirometry data, of whom 86 (53%) also had data from hemodynamic studies. Characteristics of the study subjects are presented in [Table I](#tbl1){ref-type="table"}. The subgroup of EPICure children who underwent hemodynamic assessment was representative of the entire cohort tested in school[@bib29] with respect to neonatal history, respiratory morbidity, maternal characteristics, and lung function testing results ([Table II](#dtbl1){ref-type="table"}; available at [www.jpeds.com](http://www.jpeds.com)), but were slightly older, reflecting their evaluation toward the end of the recruitment period.

Hemodynamic Assessment {#sec2.1}
----------------------

Peripheral diastolic BP and MAP were marginally higher in the EP children compared with their classmates (mean difference, 2.1 mmHg \[95% CI, −0.1 to 4.3 mmHg\] and 2.1 mmHg \[95% CI, −0.1 to 4.2 mmHg\], respectively; both *P* = .06), whereas peripheral pulse pressure was −3.6 mmHg (95% CI, −6.6 to −0.6) lower (*P* \< .05) ([Table III](#dtbl2){ref-type="table"}; available at [www.jpeds.com](http://www.jpeds.com)). AIx was significantly (*P* \< .001) higher in the EP children (7% ± 10% vs 2% ± 9%: difference, 5% \[95% CI, 2%-8%\]) and remained so after adjustment for age, sex, MAP, and height (adjusted difference, 4% \[95% CI, 0.4%-7%\]). Only a minimal difference in AIx was detected between EP children with previous BPD and those without BPD unadjusted difference \[BPD − no BPD\], 1% \[94% CI, −4 to 6\]; adjusted difference, 2% (95% CI, −4% to 7%). No relationship between AIx and gestational age or birth weight was identified in the EP children. Pulse pressure amplification was lower in the EP children than their classmates, and aortic pulse wave velocity was similar in the 2 groups. The AIx was lower in boys than in girls in the EP group, but this sex difference was not evident in the classmates, and there was no significant interaction between sex and EP status (*P* = .50).

Lung Function {#sec2.2}
-------------

Even after correction for height, age, and sex using standardized *z*-scores, children born EP had significantly worse baseline lung function (difference in *z*-scores: FEV~1~, −1.02 \[95% CI, −1.37 to −0.66\]; forced vital capacity \[FVC\], −0.49 \[95% CI, −0.83 to −0.15\]; FEV~1~/FVC ratio, −0.79 \[95% CI, −1.13 to −0.44\]; forced mid-expiratory flow \[FEF~25-75~\] −1.19 \[95% CI, −1.57 to −0.81\]) compared with their classmates, with these differences most marked in those with previous BPD ([Table III](#dtbl2){ref-type="table"}). A positive bronchodilator response was observed more frequently in the EP children than in classmates (36% vs 9%), but postbronchodilator FEV~1~ was significantly lower in the EP children, indicating some degree of fixed airway obstruction. Current or previous (within 12 months) use of bronchodilators, inhaled corticosteroids, and leukotriene antagonists was more common in the EP children (data not shown).

Relationship of Lung Function and Hemodynamic Parameters {#sec2.3}
--------------------------------------------------------

In the EP children, AIx was inversely related to baseline lung function (FEV~1~ *z*-score, r = −0.31; FEV~1~/FVC *z*-score, *r* = −0.31; FEF~25-75~ *z*-score, *r* = −0.33), and directly proportional to the percentage change in FEV~1~ after bronchodilator use (*r* = 0.36; *P* \< .01 for all comparisons) ([Figure](#fig1){ref-type="fig"}). In contrast, in the classmate controls, AIx was correlated only with FEF~25-75~ (*r* = −0.23; *P* \< .05) and percent change in FEV~1~ after bronchodilator use (*r* = 0.28; *P* = .01). Pulse pressure amplification was related to FEV~1~/FVC ratio in both EP children (*r* = 0.25; *P* = .04) and their classmates (*r* = 0.25; *P* = .02). MAP, diastolic BP, and systolic BP were not related to lung function measurements in the EP children or classmates.

On multiple regression analysis, in all subjects, AIx was independently and inversely associated with baseline lung function, with a 2.7% increase in AIx for each *z*-score decrease in FEV~1~ ([Table IV](#tbl4){ref-type="table"}). There was an additional affect of maternal smoking during pregnancy, associated with a 4.9% increase in AIx. Given that maternal smoke exposure was not recorded in all subjects ([Table I](#tbl1){ref-type="table"}), the model was also run without this variable; a similar association between baseline FEV~1~ *z*-score and AIx was observed (data not shown).

Similar findings were observed when FEV~1~/FVC and FEF~25-75~ were substituted for FEV~1~ in the model. In the model including baseline FEV~1~, there was no significant additional contribution of percent change in FEV~1~ after bronchodilator use, because of the strong inverse relationship between these outcomes. However, using percent change in FEV~1~ after bronchodilator use instead of FEV~1~ in the model, a 2.5% increase in AIx for each 5% increase in FEV~1~ after bronchodilator use was seen, with an additional 5.2% increase in AIx if the mother had smoked during pregnancy. EP birth, previous BPD, and current asthma did not contribute further to the model.

In models restricted to EP children alone, baseline FEV~1~ or percent change in FEV~1~ with bronchodilator use had similar effects as in the whole group ([Table IV](#tbl4){ref-type="table"}). Although maternal smoking in pregnancy was no longer significant (presumably because of the smaller sample size and thus the lower power of the study during subgroup analysis), it had the same size effect as in the whole group. BPD status had no statistically independent effect on AIx in these models.

Discussion {#sec3}
==========

We have demonstrated that the increased pulse wave reflection, manifested as an increased AIx value, is independently associated with impaired lung function in children born at 25 weeks of gestation or less compared with term-born classmates at age 11 years. Importantly, these abnormal large-vessel hemodynamics are not reflected in peripheral BP, the standard method of assessing hemodynamics at this age, and no association was seen between lung function and peripheral BP. This novel association is relevant to both pediatric and adult practice as increasing numbers of EP children are reaching adulthood and must be considered at increased risk for later cardiorespiratory morbidity based on these observations.

AIx not only was inversely related to baseline lung function, but also had independent associations with bronchodilator response and maternal smoking during pregnancy. Once these factors had been accounted for, whether or not there is any further detrimental effect of preterm birth over and above that manifested through the poor respiratory function is uncertain. When multiple regression analysis was limited to the children born EP, a striking independent effect of lung function remained evident in this population.

EP birth is followed by significant respiratory and nutritional problems, which lead to poor respiratory health and growth during early childhood.[@bib10; @bib19; @bib20] Integral to the preterm birth event and the consequent early abrupt changes to fetal oxygenation and hemodynamics are the maternal or fetal factors contributing to the preterm birth, as well as the associated perinatal events such as the use of supplemental oxygen or ventilator-induced lung injury. These factors further complicate the search for specific causal pathways of respiratory and cardiovascular risks. Thus, mechanisms remain speculative, but are known to include a common developmental pathway. Our data clearly demonstrate that we can no longer consider the cardiovascular or respiratory sequelae in isolation if we are to research how to optimize health following preterm birth.

Lung distensibility and elastic recoil are governed primarily by the size of alveoli and surface tension in the healthy lung, but elastin and collagen contribute as well. The alveolar ducts contain a spiral of collagen and elastin, and the interstitium contains bundles of collagen surrounding electron-dense elastin. Within the aorta, elastin contributes 40%-50% of the dry weight in healthy subjects.[@bib37] Because deposition of elastin within the aorta and in the respiratory tract occurs late in gestation, it may be disrupted after preterm birth and may influence both large arterial wall and lung composition. However, the increase in AIx value associated with increased wave reflection suggests that a structural contribution to the abnormalities might involve the elastic arteries juxtaposing the more muscular resistant peripheral arteries or the microvasculature.

Alterations in angiogenic factors related to preterm birth, such as disruption of vascular endothelial growth factor and vascular/nitric oxide signaling, can lead to structural changes of the cardiorespiratory system.[@bib38; @bib39] The role of inflammatory changes in the genesis of preterm birth and the evolution of neonatal lung disease and brain injury is a matter of much debate.[@bib40] Although systemic inflammatory mediators are thought to contribute to the association between reduced lung function and increased arterial stiffness in both healthy and ill adults, there is little causal evidence to confirm this.[@bib4] It may be hypothesized that lung epithelial injury potentiates a systemic inflammatory state, which in turn leads to endothelial dysfunction or architectural disruption of large arteries.[@bib41]

Maternal smoking during pregnancy increases fetal nicotine exposure and is likely to affect both lung function and arterial stiffness, as passive and direct smoking do in later life.[@bib42] Increased fetal carboxyhemoglobin leads to hypoxemia and, in murine models, increased oxidative stress when exposed to smoke during the neonatal period.[@bib43] Supporting this finding are altered hemodynamics in utero and in children whose mothers smoked.[@bib44; @bib45] Importantly, in this study, the negative impact of maternal smoking on AIx was in addition to that attributed to reduced lung function.

The fetal and perinatal periods are times of rapid growth and development with increased vulnerability to a wide range of insults. Although few insults in the perinatal period compare with that of being born EP, the potential impact of early life exposures for other cardiorespiratory conditions can be illuminating. Despite the clear association between COPD and cumulative tobacco smoke exposure, there is marked heterogeneity of COPD phenotypes and susceptibility, related not only to genetic susceptibility, but also to early life exposures.[@bib46] Thus, although the altered hemodynamics reported in adults with chronic lung diseases such as COPD and cystic fibrosis have been attributed to an accelerated ageing of the vasculature, these physiological changes may originate in and be triggered by early life factors.

It should be noted that this study is cross-sectional in nature, and any causal relationship can only be inferred. However, the EPICure study provides the opportunity to track cardiorespiratory status and determine future consequences. Further, this work is intended to challenge our current thinking of considering each system in isolation. AIx was based on aortic pressure waveform data, derived from radial pressure recordings, using a generalized transfer function that has not been validated in children. However, McEniery et al[@bib18] reported similar findings in this group with radial AIx, which does not rely on this transfer function. We did not have detailed data on family history of cardiovascular disease or on cardiovascular status, patent ductus arteriosus, or pulmonary hypertension in infancy. Our findings raise the question of whether a detailed evaluation of neonatal cardiovascular findings, complications, and treatments now requires study of the ontogeny of cardiovascular impairment in EP children and the extent to which treatments for BPD and cardiovascular problems may modify adult outcomes across systems.

In conclusion, the increased AIx values found at age 11 years in EP children are inversely related to baseline lung function and directly related to bronchodilator response, with an additive contribution from exposure to maternal smoking during fetal development. Children born EP who are at increased risk for future cardiovascular and pulmonary problems as adults have alterations suring childhood that are not reflected in traditional measures of peripheral BP.

Appendix {#appsec1}
========

EPICure Studies Steering Committee Members: Peter Brocklehurst (Chairman), Jane Abbott, Andrew Bush, Richard Cooke, Noreen Maconochie, Alison Matthews, David Matthews, Richard Morton, Maggie Redshaw, David Taylor, Diane Turner, Nigel Turner, and Patrick Walsh.Table IIComparison of study population and cohort of EP children tested at school at approximately 11 years of ageEP without hemodynamics (n = 121)EP with hemodynamics (n = 66)Mean (95% CI) of difference (b−a)Male sex, n (%)48/121 (40)32/66 (48)8% (−6% to 22%)White ethnicity, n/N (%)92/114 (81)45/56 (80)−1% (−14% to 11%)Gestational age, weeks25.0 (0.8)24.9 (0.8)−0.17 (−0.39 to 0.05)Birth weight, kg0.75 (0.11)0.74 (0.13)−0.01 (−0.05 to 0.03)Birth weight *z*-score−0.15 (0.76)−0.15 (0.77)0.01 (−0.23 to 0.24)BPD, n/N (%)87/121 (72)45/66 (68)−4% (−18% to 9%)Smoking in pregnancy, n/N (%)30/113 (27)13/55 (24)−3% (−17% to 11%)Details at time of test Age, years10.9 (0.4)11.3 (0.5)0.4 (0.3 to 0.5)[∗](#dtbl1fnlowast){ref-type="table-fn"} Height *z*-score−0.57 (1.03)−0.58 (0.97)−0.01 (−0.31 to 0.30) Weight *z*-score−0.60 (1.35)−0.29 (1.12)0.32 (−0.07 to 0.70) Current asthma, n/N (%)30/117 (26)14/57 (25)−1% (−14% to 13%) FEV~1~*z*-score−1.54 (1.2)−1.25 (1.2)0.30 (−0.06 to 0.66)[^1][^2]Table IIIComparison of hemodynamic and lung function values in children born EP, with and without BPD, and control classmatesEP with BPD (n = 45)EP, no BPD (n = 21)All EP (n = 66)Controls (n = 86)Mean (95% CI) difference (EP−controls)Cardiovascular Heart rate, bpm82.5 (11.8)81.1 (10.6)82.0 (11.4)79.6 (11.2)2.4 (−1.2 to 6.0) Peripheral systolic BP, mmHg107.6 (10.9)109.7 (8.9)108.2 (10.3)109.7 (9.2)−1.5 (−4.6 to 1.6) Peripheral diastolic BP, mmHg64.6 (7.3)65.2 (5.2)64.8 (6.7)62.7 (7.1)2.1 (−0.1 to 4.3) Peripheral MAP, mmHg79.4 (7.0)80.0 (5.6)79.6 (6.6)77.6 (6.7)2.1 (−0.1 to 4.2) Peripheral pulse pressure, mmHg43.0 (10.7)44.5 (7.8)43.5 (9.8)47.1 (8.7)−3.6 (−6.6 to −0.6)[∗](#dtbl2fnlowast){ref-type="table-fn"} Central systolic BP, mmHg92.3 (7.3)93.7 (7.5)92.7 (7.3)91.4 (7.2)1.4 (−1.0 to 3.7) Central diastolic BP, mmHg66.2 (7.5)66.6 (5.1)66.3 (6.8)64.1 (7.1)2.2 (−0.1 to 4.4) Central pulse pressure, mmHg26.1 (5.5)27.1 (6.2)26.5 (5.7)27.2 (5.4)−0.8 (−2.6 to 1.0) AIx, %8 (9)7 (11)7 (10)2 (9)5 (2 to 8)[†](#dtbl2fndagger){ref-type="table-fn"} Aortic pulse wave velocity, m/s4.5 (0.5)4.5 (0.6)4.5 (0.5)4.7 (0.9)−0.21 (−0.46 to 0.03) Pulse pressure amplification1.65 (0.27)1.66 (0.15)1.66 (0.24)1.74 (0.11)−0.08 (−0.14 to −0.02)[‡](#dtbl2fnddagger){ref-type="table-fn"}Lung function Respiratory rate, breaths/minute19.1 (3.0)19.3 (3.0)19.2 (3.0)17.7 (2.9)1.5 (0.5 to 2.4)[‡](#dtbl2fnddagger){ref-type="table-fn"} FEV~1~*z*-score[§](#dtbl2fnsection){ref-type="table-fn"}−1.54 (1.11)−0.63 (1.20)−1.25 (1.21)−0.23 (1.00)−1.02 (−1.37 to −0.66)[‡](#dtbl2fnddagger){ref-type="table-fn"} % of predicted82.1 (12.8)92.7 (14.1)85.5 (14.0)97.3 (11.7)−11.80 (−15.94 to −7.68)[‡](#dtbl2fnddagger){ref-type="table-fn"} FVC *z*-score[§](#dtbl2fnsection){ref-type="table-fn"}−0.89 (1.14)−0.41 (1.16)−0.74 (1.16)−0.25 (0.95)−0.49 (−0.83 to −0.15)[‡](#dtbl2fnddagger){ref-type="table-fn"} % of predicted90.2 (12.4)95.5 (13.1)91.9 (12.8)97.2 (10.5)−5.31 (−9.05 to −1.58)[‡](#dtbl2fnddagger){ref-type="table-fn"} FEV~1~/FVC *z*-score[§](#dtbl2fnsection){ref-type="table-fn"}−1.14 (1.09)−0.38 (1.30)−0.90 (1.21)−0.11 (0.9)−0.79 (−1.13 to −0.44)[‡](#dtbl2fnddagger){ref-type="table-fn"} FEF~25-75~*z*-score[§](#dtbl2fnsection){ref-type="table-fn"}−2.04 (1.12)−1.03 (1.37)−1.72 (1.29)−0.53 (1.07)−1.19 (−1.57 to −0.81)[‡](#dtbl2fnddagger){ref-type="table-fn"} % change in FEV~1~ with bronchodilator use[¶,‖](#dtbl2fnpara dtbl2fnVerbar){ref-type="table-fn"}11 (13)7 (10)9 (11)3 (5)5 (3 to 8)[‡](#dtbl2fnddagger){ref-type="table-fn"} Increase in FEV~1~ \>12%, n (%)[¶](#dtbl2fnpara){ref-type="table-fn"}18 (43%)3 (18%)21 (36%)7 (9%)27% (13% to 40%)[‡](#dtbl2fnddagger){ref-type="table-fn"} Postbronchodilator FEV~1~*z*-score[¶](#dtbl2fnpara){ref-type="table-fn"}−0.75 (0.95)−0.25 (1.14)−0.61 (1.02)0.08 (0.95)−0.69 (−1.02 to −0.36)[‡](#dtbl2fnddagger){ref-type="table-fn"}[^3][^4][^5][^6][^7][^8][^9]
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![Relationship of **A**, AIx to FEV~1~*z*-score and **B**, reversibility of FEV~1~ (change \>12%) in 11-year-old children born at ≤25 weeks gestation (EPICure) and control classmates. *REV*+, significant reversibility; *REV*−, no significant reversibility.](gr1){#fig1}

###### 

Demographic data of the EP children and classmate controls

                                                                  EP with BPD (n = 45)   EP without BPD (n =21)   All EP (n = 66)   Controls (C) (n = 86)   Mean (95% CI) difference (EP−C)
  --------------------------------------------------------------- ---------------------- ------------------------ ----------------- ----------------------- ----------------------------------------------------------------
  Gestational age, weeks                                          24.8 (0.8)             25.0 (0.7)               24.9 (0.8)        All \>37 weeks          
  Birth weight, kg                                                0.73 (0.13)            0.78 (0.12)              0.74 (0.13)                               
  Birth weight *z*-score[∗](#tblIfnlowast){ref-type="table-fn"}   −0.26 (0.69)           0.08 (0.90)              −0.15 (0.77)                              
  Male sex, n (%)                                                 24 (53)                8 (38)                   32 (48)           38 (45)                 3% (−13% to 19%)
  Smoking in pregnancy n/N (%)                                    9/36 (23)              4 /19 (21)               13/55 (24)        9/78 (12)               12% (−1% to 25%)
  White ethnicity, n/N (%)                                        27/35 (77)             18 (86)                  45/56 (80)        59/69 (86)              −5% (−18% to 8%)
  Maternal nonmanual occupation, n/N (%)                          18/30 (60)             9/18 (50)                27/48 (56)        42/70 (60)              −4% (−22% to 14%)
  Maternal continuing education after 16 years, n/N (%)           15/36 (42)             9/20 (45)                24/56 (42)        37/75 (49)              −6% (24% to 11%)
  At time of assessment                                                                                                                                     
   Age, years                                                     11.3 (0.5)             11.3 (0.6)               11.3 (0.5)        11.3 (0.6)              0.0 (−0.2 to 0.2)
   Height, cm                                                     141.6 (7.5)            141.3 (6.8)              141.5 (7.2)       147.1 (7.6)             −5.6 (−8.0 to −3.2)[†](#tblIfndagger){ref-type="table-fn"}
   Height *z*-score[∗](#tblIfnlowast){ref-type="table-fn"}        −0.55 (1.00)           −0.64 (0.90)             −0.58 (0.97)      0.25 (1.03)             −0.83 (−1.15 to −0.50)[‡](#tblIfnddagger){ref-type="table-fn"}
   Weight, kg                                                     36.3 (7.9)             35.4 (7.0)               36.0 (7.6)        40.0 (9.7)              −4.0 (−6.8 to −1.2)[‡](#tblIfnddagger){ref-type="table-fn"}
   Weight *z*-score[∗](#tblIfnlowast){ref-type="table-fn"}        −0.24 (1.13)           −0.40 (1.10)             −0.29 (1.12)      0.26 (1.15)             −0.54 (−0.91 to −0.18)[‡](#tblIfnddagger){ref-type="table-fn"}
   Current asthma, n/N (%)                                        8/37 (22)              6/20 (30)                14/57 (25)        11/ 82 (13)             12% (−1% to 26%)

Data are presented as mean (SD) unless noted otherwise. Current asthma is defined as currently symptomatic and/or with doctor diagnosis of asthma and on medication during the previous 12 months. Not all subjects reported by McEniery et al[@bib27] with hemodynamic data (68 EP children and 90 controls) had valid spirometry data; thus, the results from 66 children born EP and 86 controls form the basis of this report. Note that accurate gestational age and birth weight data were not available for controls.

Derived from Cole et al.[@bib34]

*P* \< .001 between all EP children and control classmates.

*P* \< .01 between all EP children and control classmates.

###### 

Results of stepwise multiple regression analysis with AIx as the dependent variable and including either FEV~1~*z*-score or percent change in FEV~1~ after bronchodilator use

                                                                                                B      95% CI          Adjusted *r*^2^, %
  --------------------------------------------------------------------------------------------- ------ --------------- --------------------
  All subjects                                                                                                         
   FEV~1~*z*-score                                                                                                     
   Constant                                                                                     20.6   10.1 to 31.1    
   FEV~1~*z*-score                                                                              −2.7   −3.9 to −1.5    10.6
   Heart rate, bpm                                                                              −0.2   −0.4 to −0.1    16.9
   Mother smoked during pregnancy                                                               4.9    1.0 to 8.8      20.1
   Percent change in FEV~1~ after bronchodilator use                                                                   
   Constant                                                                                     15.2   4.0 to 26.4     
   FEV~1~% change                                                                               0.5    0.3 to 0.7      14.1
   Heart rate, bpm                                                                              −0.2   −0.31 to −0.1   18.1
   Mother smoked during pregnancy                                                               5.2    1.2 to 9.3      21.9
  EP children alone[∗](#tblIVfnlowast){ref-type="table-fn"}                                                            
   FEV~1~*z*-score[†](#tblIVfndagger){ref-type="table-fn"}                                                             
   Constant                                                                                     23.7   5.4 to 41.9     
   FEV~1~*z*-score                                                                              −2.2   −4.2 to −0.2    8.7
   Heart rate, bpm                                                                              −0.2   −0.4 to −0.01   14.4
   Percent change in FEV~1~ after bronchodilator use[‡](#tblIVfnddagger){ref-type="table-fn"}                          
   Constant                                                                                     22.0   3.6 to 40.5     
   FEV~1~ % change                                                                              0.4    0.1 to 0.7      14
   Heart rate, bpm                                                                              −0.2   −0.4 to −0.01   19.9

*B*, B test; *bpm*, beats per minute.

Variables entered in all models: age at testing (years), MAP (mmHg), heart rate (bpm), height (cm), sex (male/female), BPD status (yes/no), maternal smoking during pregnancy (yes/no), and EP (yes/no).

Although smoking in pregnancy was not significant in these models, it had the same effect size as in the whole cohort.

B = 5.0; 95% CI, −0.7 to 10.7.

B = 4.8; 95% CI, −1.0 to 10.6.

[^1]: Data are mean (SD) unless noted otherwise.

[^2]: *P* \< .01.

[^3]: Data are presented as mean (SD) unless stated otherwise.

[^4]: *P* \< .05 between all EP children and classmates.

[^5]: *P* \< .001 between all EP children and classmates.

[^6]: *P* \< .01 between all EP children and classmates.

[^7]: Spirometry *z*-scores adjusting for sex, height, and age derived from Stanojevic et al.[@bib36]

[^8]: Includes 59 EP infants (17 without BPD and 42 with EP) and 79 classmates.

[^9]: Mann-Whitney test. Results are expressed as median and IQR.
